DiagnoCure licenses next-gen uPM3 to Gen-Probe
This article was originally published in The Gray Sheet
Executive Summary
Co-development pact for urine-based prostate cancer diagnostic, focusing on the PCA3 (DD3) genetic marker, corresponds with Gen-Probe's plan to broaden nucleic acid test offerings, CEO Henry Nordhoff says in Nov. 20 release. Gen-Probe will pay $3 mil. upfront to DiagnoCure, plus additional payments of up to $7.5 mil. DiagnoCure also will collect royalties of 8% on net product sales of up to $5 mil., and royalties of 16% on sales above $50 mil. "The test may offer advantages over prostate specific antigen (PSA) testing," the release notes...
You may also be interested in...
Gen-Probe’s PCA3 Prostate Cancer Test Could Be Alternative To Biopsy
Gen-Probe will seek approval for its PCA3 urine-based prostate cancer diagnostic as an alternative to the standard regimen of costly, invasive repeat biopsies for men who have abnormal PSA levels but test negative for cancer
Gen-Probe/DiagnoCure
136-patient study assessing DiagnoCure's urine-based prostate cancer diagnostic incorporating the PCA3/DD3 genetic marker shows sensitivity of 67%, specificity of 83% and negative predictive value of 90%, according to the Canadian firm. Study results were presented during the American Urological Association meeting in San Antonio May 22-26. The PCA3 assay is licensed to Gen-Probe (1"The Gray Sheet" Nov. 24, 2003, In Brief)...
Gen-Probe Cultivates Cancer Segment Through Roche HPV DNA Probe Deal
A supply and purchase agreement with Roche Molecular Systems for human papillomavirus DNA probes could enable Gen-Probe's fledgling oncology segment to introduce an HPV diagnostic in the U.S. by 2009, CEO Henry Nordhoff stated